Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$12.56 USD

12.56
2,274,762

+0.25 (2.03%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $12.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should Value Investors Pick Integra LifeSciences (IART) Now?

by Zacks Equity Research

Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Integra (IART) Up 24% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Integra (IART) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.

Zacks Equity Research

Integra LifeSciences (IART) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 40.35% and 0.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IART vs. ABMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. ABMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Integra (IART) Preliminary Q3 Results Show Recovery in Sales

by Zacks Equity Research

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

Zacks Equity Research

Why Is Integra (IART) Down 11.6% Since Last Earnings Report?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Zacks Equity Research

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 312.50% and 1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products Stock Earnings on Aug 10: CGC, SDGR & More

by Trina Mukherjee

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

Zacks Equity Research

Why Earnings Season Could Be Great for Integra LifeSciences (IART)

by Zacks Equity Research

Integra LifeSciences (IART) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

Trina Mukherjee headshot

What's in Store for Meridian Bioscience's (VIVO) Q3 Earnings?

by Trina Mukherjee

Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.

Zacks Equity Research

ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.

Zacks Equity Research

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Medical segment.

Zacks Equity Research

What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

Zacks Equity Research

What's in the Cards for Livongo Health's (LVGO) Q2 Earnings?

by Zacks Equity Research

Livongo Health (LVGO) second-quarter results are likely to reflect strength in Livongo platform.

Zacks Equity Research

Integra LifeSciences (IART) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AmerisourceBergen (ABC) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Zacks Equity Research

Livongo Health (LVGO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Livongo Health (LVGO) second-quarter results are likely to reflect growth in core Livongo for Diabetes solution.

Zacks Equity Research

Varian (VAR) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Varian's (VAR) solid Oncology platform is expected to have driven fiscal third-quarter performance.

Zacks Equity Research

Will Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?

by Zacks Equity Research

Amid the pandemic situation, GW Pharmaceuticals (GWPH), which controls its own manufacture and supply chain, is expected to have faced minimum supply-related disruption unlike others.

Zacks Equity Research

Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.